Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biorestorative Therapies Inc (NQ: BRTX )

1.445 +0.045 (+3.21%)
Streaming Delayed Price Updated: 3:48 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biorestorative Therapies Inc

< Previous 1 2 3 4 5 6 Next >
Why BioRestorative Therapies Stock Is Climbing Higher Today
BioRestorative Therapies, Inc. 
Via Benzinga
Dow Jumps Over 300 Points; Best Buy Profit Beats Views
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining more than 300 points on Thursday. The Dow traded up 0.97% to 32,978.95 while the NASDAQ rose 0.59% to 11,446.55. The S&P... 
Via Benzinga
Why Cano Health Shares Are Trading Lower By Around 23%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers Exela Technologies, Inc. (NASDAQ: XELA) shares surged 45% to $0.0701 after the company announced $51 million of new funding, amendment increases existing securitization facility to $185 million... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Dow Rises 100 Points; Macy's Posts Upbeat Earnings
U.S. stocks traded mixed midway through trading, with the Dow Jones gaining around 100 points on Thursday. The Dow traded up 0.31% to 32,764.50 while the NASDAQ fell 0.49% to 11,324.28. The S&P 500... 
Via Benzinga
BioRestorative Therapeutics (BRTX) Stock Soars 40% on Patent News
Could more patents translate to more revenue for BioRestorative Therapeutics? It's a question that BRTX stock traders are considering now. 
Via InvestorPlace
Wall Street Mixed At Open; US Weekly Jobless Claims Decline
U.S. stocks traded mixed this morning, with the Dow Jones gaining around 80 points on Thursday. Following the market opening Thursday, the Dow traded up 0.24% to 32,740.88 while the NASDAQ fell 0.58%... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
EXCLUSIVE: BioRestorative To Receive Third US Patent For Metabolic ThermoStem Program
The United States Patent and Trademark Office has issued a notice of allowance for a patent application related to BioRestorative Therapies Inc's (NASDAQ: BRTX) metabolic ThermoStem program.  
Via Benzinga
BioRestorative Therapies: This Biopharma Company Is Helping Your Body Heal Itself
Lance Alstodt, Chairman and CEO of BioRestorative Therapies, Inc. (NASDAQ: BRTX), was recently interviewed by Benzinga.  
Via Benzinga
BioRestorative Therapies Inc (NASDAQ: BRTX) Announces European Patentability Of ThermoStem® Program With Indications In Obesity And Type 2 Diabetes
By Julian Richard, Benzinga 
Via TheNewswire.com
Topics Intellectual Property
Exposures Intellectual Property
BioRestorative Therapies Inc (NASDAQ: BRTX) Announces European Patentability Of ThermoStem® Program With Indications In Obesity And Type 2 Diabetes
BioRestorative Therapies Inc (NASDAQ: BRTX) Announces European Patentability Of ThermoStem® Program With Indications In Obesity And Type 2 Diabetes 
Via News Direct
Topics Intellectual Property
Exposures Intellectual Property
BioRestorative Therapies Inc (NASDAQ: BRTX) Announces European Patentability Of ThermoStem® Program With Indications In Obesity And Type 2 Diabetes
BioRestorative Therapies (NASDAQ: BRTX), a clinical-stage biotechnology company focused on stem cell-based therapies, announced on the 8th of February that the European Patent Office had issued a... 
Via Benzinga
BioMedNewsBreaks – BioRestorative Therapies Inc. (NASDAQ: BRTX) Eyes Continued Growth of Patent Family for ThermoStem(R) Program
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
EXCLUSIVE: BioRestorative Poised To Receive European Patent For ThermoStem Program
The European Patent Office has issued a notice of allowance for a patent application related to BioRestorative Therapies Inc's (NASDAQ: BRTX) metabolic ThermoStem program.  The notice of allowance was... 
Via Benzinga
BioRestorative (NASDAQ: BRTX) Ramps Up Production In Anticipation Of Positive Phase 2 Results
BioRestorative (NASDAQ: BRTX) Ramps Up Production In Anticipation Of Positive Phase 2 Results 
Via News Direct
BioRestorative (NASDAQ: BRTX) Ramps Up Production In Anticipation Of Positive Phase 2 Results
By Julian Richard, Benzinga 
Via TheNewswire.com
BioRestorative (NASDAQ: BRTX) Ramps Up Production In Anticipation Of Positive Phase 2 Results
Chronic lumbar disc disease (cLDD) is a debilitating condition affecting millions of people worldwide. It is characterized by back pain, stiffness, and restricted movement due to damage to the bony... 
Via Benzinga
2022 Was A Year Of Growth, Funding, And Positive Results For BioRestorative Therapies
By Faith Ashmore, Benzinga 
Via TheNewswire.com
Topics Intellectual Property
Exposures Intellectual Property
2022 Was A Year Of Growth, Funding, And Positive Results For BioRestorative Therapies
2022 Was A Year Of Growth, Funding, And Positive Results For BioRestorative Therapies 
Via News Direct
2022 Was A Year Of Growth, Funding, And Positive Results For BioRestorative Therapies
BioRestorative Therapies Inc. (NASDAQ: BRTX) (“BioRestorative”) may have had a successful year of novel drug development. 
Via Benzinga
BioRestorative Therapies Announces SBIR Phase I Grant to Explore the Therapeutic Effects of ThermoStem® Targeting Polycystic Ovary Syndrome as an Indication
From BioRestorative Therapies, Inc
Via GlobeNewswire
EXCLUSIVE: BioRestorative Secures Funding Support For Programs Against Polycystic Ovary Syndrome
BioRestorative Therapies Inc (NASDAQ: BRTX) has received a Small Business Innovation Research (SBIR) Phase I grant from the Eunice Kennedy Shriver National Institute Of Child Health & Human Development... 
Via Benzinga
BioRestorative Therapies Enters Agreement with Regenexx, Granting BRTX Exclusive License Rights for Intellectual Property Related to the Development and Commercialization of its BRTX-100® Disc Program to Treat Chronic Lumbar Disc Disease
From BioRestorative Therapies, Inc
Via GlobeNewswire
EXCLUSIVE: BioRestorative Therapies Gets Exclusive License Rights From Regenexx For Development Of BRTX-100 Disc Program To Treat Chronic Lumbar Disc Disease
BioRestorative Therapies, Inc (NASDAQ: BRTX), a stem cell-based therapies clinical-stage company, forged an agreement with Regenexx, LLC, under which BRTX gets exclusive license rights for intellectual... 
Via Benzinga
BioMedNewsBreaks – BioRestorative Therapies Inc. (NASDAQ: BRTX) to Participate at RHK Capital Disruptive Growth Conference
Via Investor Brand Network
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
BioRestorative Therapies to Participate at the RHK Capital Disruptive Growth Conference on December 5-6, 2022
From BioRestorative Therapies, Inc
Via GlobeNewswire
Chronic Obstructive Pulmonary Disease (COPD) Market Expected to Reach $25 Billion By 2027
EQNX::TICKER_START (OTCQB:OCEL),(NASDAQ:BRTX),(NASDAQ:MDXG),(NYSE:NNVC),(NASDAQ:VCEL) EQNX::TICKER_END 
Via FinancialNewsMedia
The NIH Has Given BioRestorative Therapies A Stamp Of Approval
By Faith Ashmore, Benzinga 
Via News Direct
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.